Global Genomics ab signs collaboration agreement with Rheoscience A/S
Global Genomics(SM) AB (Stockholm, Sweden) announced today that Rheoscience A/S (Roedovre, Denmark) has entered into an agreement for the use tangerine® gene expression profiling to study targets in metabolic diseases. Ulf Boberg, CEO at Global Genomics stated, "This agreement is yet another confirmation of that researchers are demanding gene Expression technologies that provide higher quality information. We are very excited about expanding our customer base and broadening customer awareness."
Global Genomics develops and out-licenses innovative tools in functional genomics that provide unique insight into healthy, diseased or drug-treated cells. The company's expertise in advanced molecular biology techniques and computational analysis has resulted in the recent launch of tangerine® gene expression profiling, a proprietary solution that reveals a whole genome expression profile in a single experiment.
Rheoscience A/S is a Danish independent biotech company that, apart from own obesity research projects, provides research services within the fields of obesity and diabetes. Unique well-characterized animal models of the metabolic syndrome and internationally recognized scientists ensure fast, versatile and flexible in vivo pharmacology of lead compounds targeting metabolic disorders.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
